The R&D spending represented a 17.7% jump compared to Q2 last year. Sanofi also looked beyond in-house development in efforts to bolster its pipeline – the pharma company has had a busy July in the acquisition space. In July, the drugmaker concluded its buyout of Blueprint Medicines for $9.1bn and agreed to acquire vaccine developer Vicebio for an upfront payment of $1.5bn. In addition, Sanofi bought Dren Bio's bispecific antibody for $1.9bn in March 2025 and made a push into Alzheimer's with a $470m deal for Vigil Neuroscience in May. Despite M&A buzz, Sanofi shares have declined this year in comparison to other big pharma companies. This has been primarily due to vaccine regulation uncertainty in the US.